Announcement on the Resolution of the 10th Board of Directors of the 10th Session
Release time:
2020-08-05
证券代码:600668 证券简称:尖峰集团 编号:临2019-008
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
十届10次董事会决议公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
一、董事会会议召开情况
(一)本次董事会会议的召集、召开符合有关法律、法规及公司《章程》的相关规定。
(二)2019年4月15日,公司以传真、电子邮件及专人送达的方式发出了本次董事会会议通知。
(三)2019年4月26日,本次董事会会议在浙江省金华市尖峰大厦三楼会议室以现场表决的方式召开。
(四)公司现有九名董事,全体董事出席了会议,其中:八名董事亲自参加了会议,杜自弘董事委托董事长蒋晓萌先生代为出席会议并表决。
(五)本次董事会由董事长蒋晓萌主持,公司监事和高级管理人员列席会议。
二、董事会会议审议情况
1、通过了2018年度总经理业务报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2、通过了2018年度财务决算报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
本报告需提交股东大会审议
3、通过了2018年度利润分配预案
董事会审议并通过了该预案。
公司2018年度拟进行现金分配,以2018年末股本344,083,828股为基数,每10股派发现金红利3.0元(含税),向股权登记日登记在册的全体股东派发现金股利总额为103,225,148.40元(含税)。2018年度不进行公积金转增股本。
表决结果:同意9票、反对0票、弃权0票。
本预案将提交股东大会审议。
详见《关于2018年度利润分配预案的公告》(临2019-015)。
4、通过了聘请公司2019年度审计机构的议案
董事会审议并通过了该议案。同意继续聘请天健会计师事务所(特殊普通合伙)为公司2019年度财务及内部控制审计机构。
表决结果:同意9票、反对0票、弃权0票。
该议案将提交股东大会审议。
5、通过了为控股子公司提供担保的议案
董事会审议并通过了该议案。
对控股子公司的融资及担保,设定如下额度:
|
被担保单位 |
额度(万元) |
|
浙江尖峰药业有限公司 |
30000 |
|
上海北卡医药技术有限公司及其全资子公司 |
20000 |
|
贵州黄平谷陇铭川水泥有限公司 |
30000 |
|
浙江尖峰国际贸易有限公司 |
8000 |
|
合计 |
88000 |
同意上海北卡根据实际经营情况与其下属各全资子公司共同使用上述额度。
2、尖峰国贸是大连商品交易所的指定交割仓库,根据大连商品交易所的要求,需要本公司提供保函,对所存放的期货货物提供担保。另外,为了拓展业务,尖峰国贸目前正在申请郑州商品交易所以及上海期货交易所的交割仓库资质,也需要本公司为其提供担保。为了尖峰国贸顺利开展期货交割仓库业务,拟同意为尖峰国贸出具保函,对存放在尖峰国贸的期货货物提供担保。
在设定额度内的金融机构借款及担保事宜均授权本公司董事长决定执行。
表决结果:同意9票、反对0票、弃权0票。
详见《关于为控股子公司提供担保的公告》(临2019-010)。
本议案需提交股东大会审议。
6、通过了公司会计政策变更的议案
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
详见《关于公司会计政策变更的公告》(临2019-018)。
7、通过了2018年年度报告及其摘要
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2018年度报告全文及摘要详见上海证券交易所网站(www.sse.com.cn)。
该报告需提交股东大会审议。
8、通过了2019年第一季度报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
2019年第一季度报告详见上海证券交易所网站(www.sse.com.cn)。
9、关于公司2019年度日常关联交易的议案
董事会审议并通过了该议案。
表决结果:同意6票、反对0票、弃权0票。关联董事蒋晓萌、杜自弘、虞建红回避了该议案的表决。
详见《关于公司2019年度日常关联交易的公告》(临2019-011)。
10、通过了授权董事长利用自有资金进行委托理财的议案
董事会审议并通过了该议案。授权董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元。每笔委托理财的期限不得超过12个月。授权期限自公司本次董事会审议通过之日起3年内有效。
表决结果:同意9票、反对0票、弃权0票。
详见《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
11、通过了召开2018年度股东大会的议案
董事会审议并通过了该议案。董事会决定于2019年5月24日在浙江省金华市婺江东路88号尖峰大厦召开2018年度股东大会,并提供网络表决方式。
表决结果:同意9票、反对0票、弃权0票
详见《关于召开2018年度股东大会的通知》(临2019-017)。
12、通过了公司《章程》修订案
董事会审议并通过了该修订案。
表决结果:同意9票、反对0票、弃权0票。
详见关于修订公司《章程》的公告(临2019-014)。
该议案需提交股东大会审议。
13、通过了公司新修订的《股东大会议事规则》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《股东大会议事规则》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
14、通过了公司新修订的《董事会议事规则》
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《董事会议事规则》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
15、通过了尖峰药业增资的关联交易议案
董事会审议并通过了该议案。
表决结果:同意7票、反对0票、弃权0票。关联董事蒋晓萌、刘波回避了该议案的表决。
详见《关于尖峰药业增资的关联交易公告》(临2019-013)。
16、通过了安徽众望增资和二期技改项目的议案
董事会审议并通过了该议案。
本公司控股子公司浙江尖峰药业有限公司的控股子公司上海北卡医药技术有限公司(以下简称:上海北卡)拟出资6000万元对其全资子公司安徽众望制药有限公司(以下简称:安徽众望)进行增资。增资完成后,安徽众望注册资本由原来的4000万元增加至10000万元,上海北卡仍持有100%股权。
安徽众望拟实施二期技改项目,项目总投资17500万元。具体建设内容为:生产车间三、生产车间五、生产车间六、办公楼、研发质检楼、综合仓库一、储罐区(含泵区);新增建设用地约82亩,并对现有二车间设备设施进行局部技改。
表决结果:同意9票、反对0票、弃权0票。
17、通过了2018年度内部控制评价报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
18、通过了战略规划纲要(2019-2023)
董事会审议并通过了该议案。
表决结果:同意9票、反对0票、弃权0票。
《战略规划纲要(2019-2023)》详见上海证券交易所网站(www.sse.com.cn)。
该议案需提交股东大会审议。
19、通过了2018年度《中长期激励基金计提方案》
董事会审议并通过了该议案。根据公司《中长期激励管理办法》的规定,2018年度提取中长期激励基金3475.03万元。
表决结果:同意9票、反对0票、弃权0票。
20、通过了董事会审计委员会2018年度履职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
21、通过了独立董事2018年度述职报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票
独立董事将向股东大会报告。
22、通过了2018年度董事会工作报告
董事会审议并通过了该报告。
表决结果:同意9票、反对0票、弃权0票。
该报告将提交股东大会审议。
公司独立董事的其他独立意见:
此外,公司独立董事对上述4(关于聘请公司2019年度审计机构的议案)、5(关于为控股子公司提供担保的议案)、6(关于公司会计政策变更的议案)、9(关于公司2019年度日常关联交易的议案)、10(关于授权董事长利用自有资金进行委托理财的议案)、15(关于尖峰药业增资的关联交易议案)、19(关于2018年度《中长期激励基金计提方案》)七项决议都发表了同意的独立意见,认为:上述董事会决议的形成符合《公司法》、公司《章程》等有关规定,没有损害中小股东的利益。
三、相关附件
1、公司第十届董事会第10次会议决议
2、公司独立董事对上述相关事项的独立董事意见
特此公告
浙江尖峰集团股份有限公司
董事会
二〇一九年四月三十日
More information
2020
11-03
Jinhua Municipal Party Committee Secretary Chen Long: I wish your enterprise better and better
On the morning of October 16, Chen long, secretary of the Jinhua Municipal CPC Committee, and his entourage came to the construction site of Jianfeng Pharmaceutical's internationalization project to investigate and affirmed the good development status and clear future development ideas of Jianfeng Pharmaceutical. At the construction site, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, introduced the overall situation of the investment scale, factory layout, and production direction of the Jianfeng Pharmaceutical internationalization project to Chen Long and his entourage. Huang Jinlong, general manager of the pharmaceutical company, accompanied Chen Long and his entourage to visit the preparation workshop under construction. The construction site is neat, tidy and orderly, and the facilities and equipment are perfect and advanced, all have been unanimously affirmed by the leaders who came to investigate. When learning that the peak internationalization project has introduced international advanced equipment, built in accordance with European and American standards, and its products are oriented to the international market, Chen long said happily: "your goals are very clear and your thinking is very clear. I wish your enterprise better and better!" (this newspaper reporter)
2020
10-23
Liu Haiping, vice mayor of Pu'er City, said during the survey: "Peak is an enterprise with feelings"
On September 30, Liu Haiping, member of the standing Committee of the Pu'er Municipal CPC Committee and vice mayor of Pu'er City, Yunnan Province, and relevant responsible persons of Pu'er City and Simao District, visited the company for investigation and research, and communicated with the leaders of the group company on topics such as further strengthening cooperation between the two sides. "Yunnan Jianfeng has not only developed well in Pu'er these years, achieved good benefits and contributed considerable tax revenue, but also made great contributions to promoting the economic development of Pu'er and the stability of the southwest border region. It is our 'star enterprise' and 'baby enterprise '." Liu Haiping said so in the exchange. He said that Pu'er is an important window for the implementation of the "Belt and Road" concept. It has good conditions in natural resources, transportation, electricity, etc., and the peak is a "sentimental enterprise" and has a good foundation in the local area. Strengthen cooperation; various government departments will also earnestly "stand on the platform" and "do a good job as a shopkeeper" to serve enterprises. Chairman Jiang Xiaomeng and General Manager Yu Jianhong exchanged views with Liu Haiping and his party on the layout of peak industry and strengthening cooperation with Pu 'er. After that, accompanied by General Manager Yu Jianhong and Deputy General Manager Huang Jinlong, Liu Haiping and his party visited the Jinxi Factory of Jianfeng Pharmaceutical Factory. (this newspaper reporter)
2020
10-09
The first batch of Jianfeng Pharmaceuticals to enter Jinhua (Shanghai) Science and Technology Center
News from our newspaper On September 16, at the unveiling ceremony of the Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Innovation Center and Jinhua (Shanghai) Talent Building, Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, took over from Chen Long, secretary of the Jinhua Municipal Party Committee. The golden key with big red flowers. Spike Pharmaceuticals became one of the first seven companies to enter the center. The Yangtze River Delta G60 Jinhua (Shanghai) Science and Technology Center and Jinhua (Shanghai) Talent Building are the first "Science and Technology and Talent Enclave" in Shanghai in the nine cities of the Yangtze River Delta G60 Science and Technology Corridor, and the first cross-regional industrial collaborative innovation center in the Science and Technology Corridor. The center is located in Shanghai Lingang Songjiang Science and Technology City, with a total area of nearly 10,000 square meters. It includes two parts: science and technology innovation and talent service. There are five major centers, including talent service center, science and technology innovation exhibition center, business incubation center, enterprise research and development center, and talent project roadshow center. It is a science and technology innovation platform that integrates the functions of project incubation, recruitment of institutions, and talent recruitment. Chen Long, secretary of the Jinhua Municipal Party Committee, said in his speech at the unveiling ceremony that in the future, all scientific and technological enterprises stationed in Jinhua (Shanghai) Science and Technology Center and Talent Building can equally enjoy Jinhua's local science and technology and talent policies, so as to further break the space limitation, enable talents from the two places to share the most favorable treatment and convenient services, help enterprises to develop in Shanghai and achieve industrialization in Jinhua. At the ceremony, leaders such as Chen Long, secretary of the Jinhua Municipal Party Committee, and Cheng Xiangmin, secretary of the Shanghai Songjiang District Party Committee, awarded seven companies, including Jianfeng Pharmaceutical, the golden key to symbolize their entry. At the Yangtze River Delta Integrated Talent Cooperation Project Symposium held after the ceremony, Jiang Xiaomeng spoke as a representative of Jinhua entrepreneurs. He believed that Shanghai, as an international metropolis, has an agglomeration effect on high-end intellectual resources and grasps the first-class element resources of scientific and technological innovation in China and even the world. The establishment of G60 Jinhua (Shanghai) science and technology innovation center and talent building in the Yangtze River Delta helps Jinhua enterprises to take off in scientific and technological innovation and information exchange, which will provide strong and continuous scientific and technological support and intellectual support for the long-term development of enterprises in the future, and attract more excellent domestic and foreign talents to serve Jinhua enterprises, It plays a key role in further improving scientific research ability, innovation ability and personnel training. During the event, Jiang Xiaomeng successively accepted on-site interviews with "People's Daily", "Liberation Daily", "Zhejiang Daily" and other media. He said that the establishment of science and technology innovation and talent bases in Shanghai has greatly enhanced Jinhua's attractiveness to enterprises. "With this base, we don't need to introduce talents to Jinhua, but directly recruit talents in Shanghai, and at the same time enjoy Jinhua's various talent recruitment policies, and change Shanghai talents to Jinhua's use. This is a kind of bold. The innovation has greatly solved the dilemma of attracting talents for enterprises." As a settled enterprise, it will also make full use of its own advantages to continuously inject resource vitality into the science and technology innovation center, and continue to contribute to the long-term development of Jinhua's economy. (this newspaper reporter)
2020
09-22
Spike Pharmaceutical Added New Products
On September 3, Spike Pharmaceutical Company received the approval of the State Drug Administration for the registration of esomeprazole sodium for injection (approval number: 2020S00572). Esomeprazole sodium for injection is mainly used to treat low-risk patients with gastroesophageal reflux disease and acute gastric or duodenal ulcer bleeding when oral therapy is not applicable. It has been listed in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) ", classified as Class B. According to industry statistics, 30 companies including Zhengda Tianqing and Qilu Pharmaceutical have been approved for listing in China. In 2019, domestic sales (including urban and county-level public hospitals, community and township health centers) were about 3.317 billion yuan. Jianfeng Pharmaceutical submitted an application for registration of esomeprazole sodium for injection to the State Food and Drug Administration in November 2013 and was accepted. Up to now, Jianfeng Pharmaceutical has invested nearly 15 million yuan in research and development for the project and has a corresponding production line. This time to obtain the injection of esomeprazole sodium drug registration approval, marking the peak pharmaceutical has the drug production, sales qualification, will further enrich the peak pharmaceutical product line, help to enhance the competitiveness of the peak pharmaceutical business. (Lu Yating, Liu Yang)
2020
09-11